Lymphoid Malignancy Flashcards
(37 cards)
Lymphoma
A cancer of lymphoid origin. This can present with enlarged lymph nodes, extranodal involvement or bone marrow involvement.
Systemic B Symptoms
Weight loss (> 10% in 6 months), fever, night sweats, pruritus, fatigue
How is the classification of lymphoma decided
Biopsy of site of tumour
Clinical examination and imaging (CT) tell us where it is.
Science of lymphoma
Malignancy occurs in the lymphoid region (germinal centre). To the lymph glands and the secondary lymphoid tissue.
Lymphoproliferative Disorders
Acute lymphoblastic leukaemia (ALL)
Chronic lymphocytic leukaemia (CLL)
Hodgkin lymphoma
Non-Hodgkin lymphoma (NHL)
Most common lymphoproliferative disorder
Non-hodgkin Lymphoma (High grade diffuse large B-cell lymphoma)
Acute Lymphoblastic Leukaemia
Neoplastic disorder of lymphoblasts diagnosed by >20% lymphoblasts present in the bone marrow.
Epidemiology of ALL
Incidence 1-2/100,000 population/year
75% cases occur in children < 6 years
75-90% cases are of B-cell lineage
Presentation of ALL
2-3 week history of bone marrow failure (with possible raised white cell count) or bone and joint pain, infection, night sweats
Emergency treatment in every lymphoma
Steroids
Standard treatment of ALL
Induction chemotherapy to obtain remission
Consolidation therapy
CNS directed treatment
Maintenance treatment for 18 months
Stem cell transplantation if they are high risk (20-30% mortality)
Indicators of poor prognosis in ALL
Increasing age
Increased white cell count
Immunophenotype (more primitive forms)
Cytogenetics/molecular genetics t(9,22), t(3;11)
Adult outcome ALL
complete remission rate 78–91%
leukaemia-free survival at 5y 30–35%
Child outcome ALL
5y overall survival ~90%
Chronic Lymphocytic Leukaemia
Diagnosed by blood >5x10^9/L lymphocytes.
Bone marrow >30% lymphocytes
Characteristic Immunophenotyping (CD 19, 20, 23) & CD5 positive (not supposed to be there)
Epidemiology of CLL
> 1700 new cases CLL per year in the UK
Commonest leukaemia worldwide
2 males: 1 female
Presentation of CLL
Often assymptomatic at presentation
Frequent findings: Bone marrow failure (anaemia, thrombocytopenia) Lymphadenopathy Splenomegaly (30%) Fever and sweats (B-symptoms) (< 25%)
Less common findings:
Hepatomegaly
Infections
Weight loss
CLL associated findings
Immune paresis (loss of normal immunoglobulin production)
Haemolytic Anaemia
CLL stage A
<3 lymph node areas
median survival is same as age matched control
CLL stage B
3 or more lymph node areas
Median survival is around 8 years
CLL stage C
Stage B + anaemia or thrombocytopenia
Median survival is around 6 years
Indications for treatment of CLL
Progressive bone marrow failure Massive lymphadenopathy Progressive splenomegaly Lymphocyte doubling time <6 months or >50% increase over 2 months Systemic symptoms Autoimmune cytopenias
Treatment of CLL
Often nothing – “watch and wait”
Cytotoxic chemotherapy e.g. fludarabine, bendamustine
Monoclonal antibodies e.g. Rituximab, obinutuzamab
Poor Prognostic Markers of CLL q
Advanced disease (Binet stage B or C) Atypical lymphocyte morphology Rapid lymphocyte doubling time (<12 mth) CD 38+ (plasma cell marker) expression Loss/mutation p53; del 11q23 (ATM gene) Unmutated IgVH gene status